文献速递浆细胞疾病造血干细胞移植与细胞治疗

自体造血干细胞移植后早期M蛋白免疫重建是高危细胞遗传学多发性骨髓瘤患者的良好预后标志

Early M-protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma.
PubMed 文献 · Br J Haematol · 2024-01-21

本研究探讨移植后M蛋白免疫重建对多发性骨髓瘤患者预后的影响。290例患者中25.9%(75/290)出现M蛋白免疫重建,该组完全缓解率和MRD阴性率更高。在细胞遗传学高危组中,M蛋白免疫重建预示更好的无进展生存和总生存。

要点

  • 移植后M蛋白免疫重建见于25.9%(75/290)的多发性骨髓瘤患者。
  • M蛋白免疫重建组完全缓解率85.3% vs 69.3%(p=0.013),MRD阴性率81.9% vs 66.5%(p=0.014)。
  • 细胞遗传学高危组中,M蛋白免疫重建者PFS 80 vs 31个月(p=0.010),OS未达到 vs 91个月(p=0.026)。

核心结论

  • M蛋白免疫重建患者预后较好可能与获得更深缓解有关。
  • 在高危患者中,早期出现M蛋白免疫重建可能提示更好的预后。

研究设计与样本

  • 本研究为观察性研究,纳入290例接受自体造血干细胞移植的多发性骨髓瘤患者。
  • 研究分析移植后血清免疫固定电泳出现暂时性异常蛋白带(M蛋白免疫重建)对预后的影响。

主要发现

  • M蛋白免疫重建见于25.9%(75/290)的患者。
  • M蛋白免疫重建组完全缓解率85.3% vs 无M蛋白免疫重建组69.3%(p=0.013),MRD阴性率81.9% vs 66.5%(p=0.014)。
  • 两组总体中位生存时间无显著差异,M蛋白免疫重建组总生存80 vs 72个月(p=0.076),无进展生存未达到 vs 105个月(p=0.312)。
  • 细胞遗传学高危组中,M蛋白免疫重建者无进展生存80 vs 31个月(p=0.010),总生存未达到 vs 91个月(p=0.026)。
  • 修订版国际分期系统III期患者中,M蛋白免疫重建者无进展生存80 vs 20个月(p=0.025),总生存57 vs 32个月(p=0.103)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The presence of transient abnormal protein banding (M-protein immune reconstitution) in serum immunofixation electrophoresis after autologous haematopoietic stem cell transplantation in patients with multiple myeloma has been reported. The purpose of this study was to investigate the impact of post-transplant M-protein immune reconstitution on the prognosis of patients with multiple myeloma. M-protein immune reconstitution was observed in 25.9% (75/290) of patients. The CR rate and MRD negativity were higher in the M-protein immune reconstitution group (85.3% vs. 69.3%, p = 0.013, 81.9% vs. 66.5%, p = 0.014). Although there were no significant differences between the groups, the overall median survival time was longer in the M-protein immune reconstruction group (80 vs. 72 m, p = 0.076; not reached vs. 105 m, p = 0.312). Among patients in the cytogenetic high-risk group, the occurrence of M-protein immune reconstitution predicted better PFS and OS (80 vs. 31 m, p = 0.010; not reached vs. 91 m, p = 0.026). Additionally, in revised-International Staging System stage III patients, PFS and OS were better in those who achieved M-protein immune reconstitution (80 vs. 20 m, p = 0.025; 57 vs. 32 m, p = 0.103). The better prognosis of M-protein immune reconstitution patients may be associated with the acquisition of a deeper response. In high-risk patients, early acquisition of M-protein immune reconstitution may suggest a better prognosis.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhu H, Liu J, Gu J, et al. Early M-protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma. Br J Haematol. 2024. PMID: 38246862. doi:10.1111/bjh.19275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。